drugset / Trial / NCT00968617

A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)

NCT00968617

Phase 2 Terminated 7 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will define an effective starting dose for subcutaneous administration of MK2578 to correct anemia in erythropoiesis-stimulating agent (ESA)-naive patients with chronic kidney disease (CKD) who are not on dialysis while evaluating its safety.

Timeline

Start
2009-11
Primary completion
2010-04
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic
Subject MK2578 Unknown 1 ug/kg Subcutaneous
Subject MK2578 Unknown 2 ug/kg Subcutaneous
Subject MK2578 Unknown 3.6 ug/kg Subcutaneous